1. Home
  2. BNGO vs LIXT Comparison

BNGO vs LIXT Comparison

Compare BNGO & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.14

Market Cap

24.3M

Sector

Industrials

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$3.05

Market Cap

25.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
LIXT
Founded
2003
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
25.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
BNGO
LIXT
Price
$1.14
$3.05
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$6.33
N/A
AVG Volume (30 Days)
315.2K
103.3K
Earning Date
03-30-2026
03-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$28,720,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$24.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.06
$0.64
52 Week High
$6.32
$6.26

Technical Indicators

Market Signals
Indicator
BNGO
LIXT
Relative Strength Index (RSI) 27.43 39.81
Support Level $1.06 $3.04
Resistance Level $1.23 $3.08
Average True Range (ATR) 0.11 0.38
MACD -0.03 -0.05
Stochastic Oscillator 10.16 33.33

Price Performance

Historical Comparison
BNGO
LIXT

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: